Why Participation Needs a Defined Role
An adaptive platform makes decisions that can affect several treatment arms, participant groups, and sponsors over time. Scientific experts outside the immediate trial team can help assess whether a proposed change is methodologically or clinically coherent. Patients and caregivers can identify how the trial’s procedures and choices may be experienced in practice. These perspectives can improve governance, but only when the platform specifies what input is needed, when it is sought, and who remains responsible for the decision.
Participation is not a substitute for accountability. An adviser may identify a risk or recommend a change, while the body or role formally assigned authority considers that advice and makes the decision. Conversely, a consultation that occurs after a decision is effectively settled is unlikely to provide meaningful input. The aim is neither to transfer every decision to external participants nor to seek their views as a symbolic gesture. It is to connect appropriate knowledge to a decision while preserving clear responsibility.
Match the Perspective to the Decision
The right participant depends on the question. A trial statistician external to the platform may be well placed to examine whether a proposed analysis change is technically coherent. A clinician with experience in the condition may assess whether a proposed eligibility criterion or treatment pathway is clinically plausible. A patient representative may identify that a visit schedule is difficult to sustain, that an outcome is hard to interpret as meaningful, or that the wording of participant materials is unclear. No one person can be assumed to represent every relevant scientific or patient perspective.
Some questions need more than one perspective. When a change combines a scientific rationale with a change in participant burden, for example, the platform should seek both kinds of input rather than ask one adviser to speak beyond their expertise. Where a decision affects one arm, the relevant arm-specific expertise may be particularly important. Where a decision affects shared procedures or several arms, the platform should also consider the consequences across the platform. The governance role should reflect the reach of the decision, not just the identity of the person who proposed it.
| Decision question | Useful external perspective | Contribution to the decision |
|---|---|---|
| Is a proposed scientific change coherent with the platform’s objectives? | Relevant clinical, methodological, or disease-area expert | Identifies technical assumptions, clinical implications, and plausible alternatives |
| Could a proposed procedure or schedule create avoidable burden? | Patient or caregiver representatives with relevant experience | Explains practical barriers and how burden may be experienced |
| Does a change affect both scientific interpretation and participant experience? | Relevant scientific experts and patient representatives | Provides distinct inputs that can be considered together without treating one as a substitute for the other |
| Does a proposal require an urgent or highly specialized judgment? | Ad hoc adviser with the needed expertise, if permitted by governance arrangements | Provides focused advice while the accountable decision-maker retains responsibility |
A useful design starts by naming the decision, rather than recruiting a broad panel and hoping it will prove useful. Ask: what uncertainty does the decision-maker need help with; which perspectives can address it; what information can those participants appropriately receive; and what authority, if any, do they have? The answers should be reflected in the platform’s governance arrangements before a contentious decision arises.
Define the Role Before Soliciting Advice
For each participation role, make the remit concrete. It should identify the topics on which input is sought, the expected timing, the materials participants will receive, any confidentiality requirements, and how the responsible decision-maker will use the input. It should also state whether the participant is advising, reviewing a proposal, or exercising an explicitly delegated function. If the participant has no authority to make the decision, say so plainly. That boundary protects both the adviser and the decision process from mismatched expectations.
A bounded remit does not mean a narrow or scripted conversation. An expert asked to review an amendment may raise an unanticipated methodological concern. A patient representative asked about visit burden may also identify that a proposed outcome measure is difficult to understand. The chair or responsible body should allow relevant observations and explain how they will be routed for consideration, while keeping the decision question clear.
Participation also requires practical preparation. Provide materials early enough to review, explain technical terms, distinguish settled facts from open questions, and give participants a clear way to raise concerns. For patient representatives, this can include accessible formats, plain-language summaries, support for preparation, and reasonable compensation for time and expertise. These measures do not guarantee that a participant can speak for a whole community; they make it more feasible for that person to contribute their own perspective.
Worked Example: Reviewing a Proposed Eligibility Change
A hypothetical platform is considering widening an arm’s eligibility range to include patients with a less severe form of the condition. The proposal could affect how results are interpreted and whether people in the expanded group find the trial acceptable. The governance body asks an external disease-area clinician and two patient representatives with relevant experience to review the proposal before it decides.
Define the question. The clinician is asked whether the proposed eligibility range is clinically coherent and what interpretive concerns it could create. The patient representatives are asked how the change might affect the relevance of participation for people with less severe symptoms, and whether the screening requirements could create burdensome or confusing expectations.
Consider the input. In this hypothetical consultation, the clinician says the wider range is clinically plausible but notes that the two severity groups may differ in their expected course. The patient representatives say that inclusion could make the trial relevant to more people, but that participants should be told clearly why severity affects eligibility. These are different contributions: the clinician identifies an interpretive issue; the representatives identify a communication and relevance issue.
Use the advice without delegating the decision by default. The accountable governance body considers whether the proposal and its planned interpretation address the clinical concern, and whether participant-facing explanations address the concern about clarity. It may approve, revise, defer, or decline the proposal under its established authority. It should not describe the advisers’ comments as approval, and it should not treat one representative’s view as the opinion of every eligible patient.
A Practical Justification for Role Design
Role design can be treated as a simple chain of reasoning. First identify the decision and the uncertainty that matters to it. Next identify the knowledge or experience needed to reduce that uncertainty. Then select participants whose expertise or experience is relevant, while checking whether their relationship to the platform creates a conflict that must be managed. Finally, specify how the accountable decision-maker will consider their input. If any link is missing, participation may be ineffective: the wrong people are asked, they lack the information needed to contribute, or their advice has no identifiable route into the decision.
This reasoning also explains why a standing group is not always the best solution. A standing group can build familiarity with the platform and support continuity, but its members may not cover the expertise needed for every arm or decision. An ad hoc adviser can fill a specific gap, but may have less context and require more orientation. The choice should depend on the recurring needs of the platform, the specific question, and the burden of maintaining each arrangement.
State what is being considered and whether its effects are platform-wide, arm-specific, or both.
Separate scientific or clinical uncertainties from questions about participant experience and practical feasibility.
Identify who can contribute, what materials they need, and whether their role is advisory or carries explicitly assigned authority.
The responsible decision-maker should be able to explain how relevant advice affected the decision, or why it did not change it.
Worked Example: Choosing Between a Standing Group and an Ad Hoc Expert
A hypothetical platform repeatedly considers changes to a shared assessment procedure, but a new arm also proposes a specialized laboratory test. The platform has a standing patient advisory group familiar with the shared procedures. No member of the usual external scientific advisory group has experience with the new test.
For the shared assessment procedure, the standing patient group is appropriate because the question concerns recurring participant experience across the platform. It can comment on burden and clarity, while the relevant scientific reviewers assess whether the procedure remains fit for the platform’s purpose.
For the specialized test, the platform should consider an ad hoc expert with relevant laboratory and clinical knowledge. The standing group’s familiarity with the platform does not make it qualified to evaluate the test’s technical suitability. Patient representatives may still be asked a distinct question about the test’s practical burden, if that is relevant and they receive an understandable explanation.
The role design therefore uses continuity where it is valuable and targeted expertise where it is missing. Neither the standing group nor the ad hoc expert automatically acquires decision authority. The platform’s assigned decision-maker remains responsible unless its governance documents explicitly delegate that authority.
Diagnosing Weak Participation
Several observable signs suggest that the process is not working. Participants receive papers too late to review them; the question is so broad that no one knows what advice is useful; patient input is sought only after the proposal has become difficult to change; or technical material is presented without enough explanation to support informed discussion. Another warning sign is that input is repeatedly collected but decision-makers cannot say how it was considered. These problems call for better timing, framing, or access to information—not simply additional meetings.
Conflicts and other relationships also matter. An expert or representative may have a professional, financial, institutional, or personal connection relevant to a proposal. The earlier material on conflicts of interest in platform decisions provides the basis for identifying and managing those interests. Participation should not be treated as proof of independence; nor should a disclosed interest automatically make a person’s contribution unusable. The governance process must determine whether the interest affects the role and manage it accordingly.
Patient representation has its own limitations. A person’s experience can be valuable without being statistically representative of all patients. Different patients may have different priorities because of disease severity, access to care, age, location, or other circumstances. The platform should describe the contribution accurately—for example, as the view of a particular representative or a discussion among a defined group—not as a universal patient preference. Broadening participation or seeking additional perspectives may help when a decision affects groups not represented in the consultation.
Worked Example: Interpreting Advice About Visit Burden
A hypothetical amendment would add one remote questionnaire each week for six weeks. Two patient representatives review the proposal. One says weekly completion seems manageable; the other says it would be difficult during periods of worsening symptoms.
The input does not establish that all participants will find the schedule either manageable or burdensome. It identifies a difference in experience and a relevant circumstance: symptom worsening. The decision-maker should consider whether the burden can be reduced or whether the schedule needs a clearer rationale, and should avoid describing the consultation as a unanimous endorsement. If the schedule is retained, the decision should still be based on the platform’s full remit and evidence, not on the assumption that these two views settle the question.
Common Pitfall and Alternatives
A common mistake is to treat consultation as delegation: “The patient representatives agreed, so the platform’s decision is settled.” This reasoning is faulty when those representatives were asked to advise rather than decide, when their remit did not cover the full question, or when their views do not represent every affected patient. The correction is to state the role in advance, consider the advice alongside other relevant information, and leave the decision with the formally accountable decision-maker unless authority was explicitly assigned otherwise.
There are several workable participation models, each with trade-offs. A standing advisory group supports continuity but may not have all the expertise needed for a particular question. An ad hoc consultation can bring in a targeted perspective but may lack platform-wide context. Individual advisers can provide focused input, while a group discussion can reveal differences among participants; neither format guarantees a complete range of views. A role with delegated authority can increase participants’ formal influence, but it requires explicit governance provisions, appropriate information, and clarity about accountability. The platform should select the least complex arrangement that can answer the decision’s actual needs, not assume one model fits every decision.
These arrangements also have limits. Participation cannot remove uncertainty, guarantee consensus, or replace the decision-maker’s responsibility to weigh competing considerations. It cannot make one expert authoritative outside their expertise or turn a small number of patient experiences into a population estimate. Its value is more specific: it can expose assumptions, improve the relevance of questions, and bring otherwise overlooked consequences into the decision process.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions below.
- A proposal changes a shared visit schedule and adds an arm-specific laboratory procedure. Which perspectives might be useful for each part, and why?
- Why is it inaccurate to say that one patient representative’s support establishes that a change is acceptable to all patients?
- A standing scientific advisory group has no expertise in a specialized test proposed for a new arm. What is a reasonable response, and what should happen to decision authority?
- What are two signs that patient consultation is unlikely to influence a decision meaningfully?
- A consultation produces two different views about a proposed procedure. What should the decision-maker conclude from that difference?
Solutions. (1) Patient representatives can inform the practical burden of the shared schedule; relevant scientific or clinical experts can assess its purpose and implications. For the specialized procedure, seek expertise relevant to that test, and ask patients a distinct burden question if useful. (2) One person reports an individual or defined group perspective; patients may differ, and the consultation does not estimate population preferences. (3) Seek a suitably qualified ad hoc expert. The advisory group’s gap does not confer authority on the new expert; the assigned decision-maker retains responsibility unless authority is explicitly delegated. (4) Examples include receiving materials too late to review and being asked only after the proposal is effectively settled. (5) The difference reveals variation in experience or priorities; it is not evidence of consensus. The decision-maker should consider both views and their relevance to the proposal.